Jong-in Han
Ewha Womans University · 医学
研究室紹介
Professor Jong-in Han's research lab specializes in anesthesiology and critical care medicine, with a primary focus on optimizing anesthetic techniques and minimizing postoperative complications. The lab investigates the neuroprotective and anti-inflammatory effects of anesthetic agents such as dexmedetomidine and opioids, particularly in vulnerable populations like elderly patients and those with Alzheimer’s disease. Research also centers on airway management, including the use of specialized endotracheal tubes and bronchial blockers for one-lung ventilation, as well as the mechanisms behind opioid-induced cough reflex during anesthetic induction. The lab integrates preclinical models with clinical studies to improve patient outcomes in surgical and intensive care settings.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15Recently, we encounter several articles regarding urinary trypsin inhibitor (UTI) published nationally When we take a glance at these articles, it feels like UTI acts as a miraculous medicine on patients under general anesthesia because of its protection effect against surgical stress. Yet, even after the first report on antitryptic action of urine by Bauer and Reich III in 1909 [3]; the start of use of the term UTI by Astrup and Sterndorff in 1955 [4]; and numerous animal experiments and clinic
Alzheimer’s disease (AD), one of the most prevalent neurodegenerative diseases is associated with pathological autophagy-lysosomal pathway dysfunction. Dexmedetomidine (Dex) has been suggested as an adjuvant to general anesthesia with advantages in reducing the incidence of postoperative cognitive dysfunction in Dex-treated patients with AD and older individuals. Several studies reported that Dex improved memory; however, evidence on the effects of Dex on neuronal autophagy dysfunction in the AD
Since Bohrer et al. [1] reported in 1990 that administering fentanyl through a central venous catheter induces the cough reflex, it has become well-known that remifentanil and fentanyl used for inducing general anesthesia cause a cough in various types of clinical situations. This has led to many clinical studies [2-4] thus far, and the research paper of Yoo et al. [5] is also included in this group. The proposed mechanisms through which opioids induce a cough are as follows: (1) pulmonary ch
Background: This study compared the modified BronchoCath double-lumen endotracheal tube (DLT) with the Univent bronchial blocker and Arndt's wire-guided endobronchial blocker (WEB) to determine whether there were objective advantages of one over the other during anesthesia with one lung ventilation.
We wanted to determine an adequate combination of target effect-site concentrations of remifentanil and propofol during anesthetic induction with target controlled infusion (TCI). We also determined whether increasing remifentanil concentrations might reduce propofol consumption at loss of consciousness (LOC).
We wanted to determine an adequate combination of target effect-site concentrations of remifentanil and propofol during anesthetic induction with target controlled infusion (TCI).We also determined whether increasing remifentanil concentrations might reduce propofol consumption at loss of consciousness (LOC). Methods: Sixty ASA 1 or 2 patients were randomly allocated according to the target effect-site concentration of remifentanil and propofol (R7P3: remifentanil 7 ng/ml + propofol 3μg/ml, R5
Propofol 1,2) (2.9 mg/kg) (2.5 mg/kg) Marsh 3) 50% 25% . opioid propofol . (TCI, target controlled infusion) (TIVA, total intravenous anesthesia) opioid propofol TCI . propofol TCI Diprifusor TM (Master TCI: Fresenius Vial S.A., France) (pharmacokinetic model) . 4) Stelpump TCI